Kineticos believes the $40+ billion outsourced market will continue to expand with a growing number of therapeutic companies seeking services. This comes at a time of a service disconnect; for example, in cell and gene therapy – a Kineticos’ area of investment – there is simply not enough capacity and poor service offerings.
Kineticos works with companies at all stages of their life cycle, from start-up to commercialization.
){kind=logo}
May 15, 2025 – Research Triangle Park, NC – Kincell Bio announced the completion of a $22 million round, led by…
)
Experic, a contract development and manufacturing organization (CDMO) and clinical supply services company serving the biopharmaceutical industry, today announced the…
){kind=logo}
New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK |…